- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA (2015))|
|International Nonproprietary Names|
|APN-311 | Ch14.18 | MAb-14.18 | Unituxin®|
|Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
A patent search identifies US20140170155  as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay.
|GtoPdb PubChem SID||249565662|
|Search PubMed clinical trials||dinutuximab|
|Search PubMed titles||dinutuximab|
|Search PubMed titles/abstracts||dinutuximab|